Skip to main content
SpringerLink
Log in

ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kamangar F, Nasrollahzadeh D, Safiri S, et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):582–97.

    Article  Google Scholar 

  2. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393:2636–46.

    Article  PubMed  Google Scholar 

  4. Kamitani N, Migita K, Matsumoto S, et al. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy. Surg Today. 2019;49:1022–28.

    Article  CAS  PubMed  Google Scholar 

  5. Harada T, Tetsuya T, Ueno J, et al. Prognostic impact of the loss of skeletal muscle mass during neoadjuvant chemotherapy in older patients with esophageal cancer. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12379-2.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by Japan Agency for Medical Research and Development (AMED) under Grant No. JP22ck0106755h0001. We thank Jane Charbonneau, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Rehabilitation, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

    Tsuyoshi Harada MSc & Tetsuya Tsuji MD, PhD

  2. Department of Rehabilitation Medicine, Keio University Graduate School, Shinjuku, Tokyo, Japan

    Tsuyoshi Harada MSc

  3. Department of Rehabilitation Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan

    Tetsuya Tsuji MD, PhD

  4. Department of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

    Takeo Fujita MD, PhD, FACS

Authors
  1. Tsuyoshi Harada MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Tsuji MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Fujita MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsuyoshi Harada MSc.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harada, T., Tsuji, T. & Fujita, T. ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer. Ann Surg Oncol 29, 8140–8141 (2022). https://doi.org/10.1245/s10434-022-12380-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12380-9

Search

Navigation